tbuckley/cabot-search huggingface dataset:
Abstracts: Part I
Authors: A Avgerinos, F Nevens, S Raptis, J Fevery, Study Above, M Group, A Adler, D Armonis, N Bac, B Bourgeois, T Burtin, J Darcis, M Decruyenaere, A Deman, M Elewaut, D Hautekeete, L Katsaros, S Lepoutre, G Natens, H Poulianos, Ch Reynaert, H Tzathas, P Van Buuren, A Van Der Spek, A Jawhari1, P Mccrea, M Farthing1, M Pignatelli, R Sostegni, G Rocca, A Musso, M Astegiano, S Greco, M Fiorentini1, M Rizzetto, A Pera, S Rosenstock, L Andersen, T Bonnevie, M Louha1, K Poussin, N Ganne4, H Zylberberg2, C Vons5, O Soubrane3, S Pol2, B Nalpas2, M Beaugrand4, P Berthelot2, D Franco5, J Trinchet4, C Brechot12
Journal: Gut (1996)

The additional efficacy of S to emergency ES in cirrhotics with an acute upper gastrointestinal bleeding episode was assessed.Immediately after admission, 205 subjects were randomly assigned to receive continuous iv infusion of S (6 mg/24 hr for 120 hr), or placebo (PI) in a double blind way.Additionally, iv boluses S (250 gg) or PI were injected: a) after start of infusion, b) before endoscopy and c) if active bleeding occurred.ES was performed between 1 to 8 h after initiation of treatment.The study drug was continued in 151 pts (74%) in which oesophageal varices were the origin of bleeding (S = 75, PI = 76).Overall failure during the 5 day study period was defined as: death or clinical signs of rebleeding or the requirement of an excess of blood products or rescue therapy.Both groups S/PI were comparable with regards to age (mean ± sd = 59.5 yrs + 12.1/58.8yrs 3.9), gender (M: 52/52, F: 23/24), Child's-class (A = 10/11; B = 38/39; C = 26/25) and alcoholic origin (40/46).Overall failure was observed in 32 subjects (S) and 51 (Pl) with p = 0.003.During the infusion 2 patients (2.7%) died in S and 7 (9.2%) in PI (p = 0.17); units of blood products transfused: 2.6 ± 0.35 (S) vs 3.6 ± 0.35 (Pl) (i.t.t., p = 0.05).In conclusion the results of this study suggest that the early administration of natural S increases the efficacy of ES in the control of acute bleeding from oesophageal varices in cirrhotics.
Progesterone administration and progressive sleep apneas
Authors: K. P. Strohl
Journal: JAMA (1981)

Nine adult patients with obstructive sleep apnea syndrome were administered medroxyprogesterone acetate, 60 to 120 mg/day, and the effect of medroxyprogesterone on clinical symptoms and obstructive apneas during sleep was assessed. Four patients responded with resolution of daytime sleepiness, disappearance of pedal edema, and a decrease in the number of obstructive apneas during sleep. Cessation of therapy led to a return of daytime sleepiness in three and an increase in obstructive apneas in all four subjects. Two responders experienced side effects of alopecia or decreased libido. Before medroxyprogesterone therapy, responders were distinguished from nonresponders only by the presence of a significantly lower resting arterial oxygen tension during wakefulness. We characterize a subgroup of patients who benefit from medroxyprogesterone therapy by reducing obstructive apneas during sleep. (<i>JAMA</i>1981;245:1230-1232)
Penicillin in H. influenzae Meningitis: Correction
Journal: BMJ (1946)

offensive.Blood urea 0.033%.Blood pressure 230/150.An ophthalmoscopic examination by Mr. V. M. Metivier gave the following resuit: " Retinitis of pregnancy marked, papilloedema very marked in both eyes; retinal detachment in lower quadrant of right eye ; extensive retinal detachment of left eye, several patches of
Correction
Journal: Hepatology (2006)

A Randomized Trial of Endoscopic Treatment of Acute Gastric Variceal Hemorrhage: N-Butyl-2-Cyanoacrylate Injection Versus Band Ligation" by Tan,, the following corrections should be noted:On page 694, column 1, line 3 from bottom the P value should be P Ͻ .001.The corrected sentence should read as:In multivariate analysis, the association of HCC (presence vs. absence of HCC, relative hazard: 4.473, 95% CI: 2.547-7.855,P Ͻ .001) and serum creatinine (relative hazard: 2.015, 95% CI: 1.177-3.448,P ϭ .011)were two independent risk factors determining survival.On page 695, Table 3, line 3 in the table footnotes,the P value should be P Ͻ .001.The corrected sentence should read as:The association of hepatocellular carcinoma (HCC) (presence vs. absence of HCC, relative hazard: 4.473, 95% CI: 2.547-7.855,P Ͻ .001) and serum creatinine (relative hazard: 2.015, 95% CI: 1.177-3.448,P ϭ .011)were two independent risk factors determining survival.
Obliterative Bronchiolitis
Authors: Alan F. Barker, Anne Bergeron, William N. Rom, Marshall I. Hertz
Journal: New England Journal of Medicine (2014)

First recognized as an occupational disorder, obliterative bronchiolitis is now the primary noninfectious pulmonary complication of allogeneic hematopoietic stem-cell transplantation and lung transplantation. This review includes an update on recognition, treatment, and prevention.
Family Medicine
Authors: Marjorie A. Bowman
Journal: JAMA (1995)

Some of the more important developments in family medicine include new approaches to cancer prevention through aspirin therapy and diet, new information on measles vaccine, better methods to increase compliance in women with abnormal Papanicolaou test results, new understanding of regimens to prevent atherosclerotic disease and its complications, helpful information concerning diagnosing and treating musculoskeletal disorders, and hope for using hormones in symptomatic patients after breast cancer. Health maintenance practices may change as a result of a study showing that aspirin taken at least twice weekly (in variable but low doses) was associated with a one-third reduction (relative risk, 0.68) in colon cancer and a one-half reduction (relative risk, 0.51) in metastatic and fatal colon cancer in more than 50 000 men.<sup>1</sup>While this study does not prove directly that aspirin reduces the risk, it suggests yet one more benefit from a practice already followed by many patients for
Transpapillary Cholecystoscopy
Authors: E C Foerster, M U Schneider, W Matek, W Domschke
Journal: Endoscopy (1989)

This report describes the inspection of the inside surface of the gallbladder and the cystic duct by a newly available catheter and endoscopic system, with the aid of retrograde endoscopy. Using our newly developed endoscopic retrograde catheter system, we were able to cannulate the gallbladder in nearly 80% of all cases. No papillotomy is needed. Owing to its high degree of flexibility and relative robustness, coupled with brilliant optical quality, the new 0.5 mm miniscope permits careful and virtually complete inspection of even such small structures as the tortuous cystic duct.
Ambulatory electrocardiographic monitoring. Technique and clinical indications
Authors: J. S. Schroeder
Journal: JAMA (1976)

THE BREVITY of the standard 12-lead resting electrocardiogram (about 30 seconds) seriously limits its value in the detection of potentially lifethreatening cardiac arrhythmias or in estimating the effectiveness of antiarrhythmic therapy. Whereas a standard ECG records 50 to 100 cardiac cycles, the ambulatory ECG records over 100,000 cycles in one or two leads during an average 24-hour day. Not only does the ambulatory ECG provide a better overall estimate of a patient's arrhythmias, but it can detect problems that only occur at particular times of the day or in response to stress such as physical exertion or emotional excitement.<sup>1</sup> Current methods of obtaining and processing ambulatory ECG tape recordings and primary areas of clinical application using this technique will be described, based on more than five years' experience in the Cardiology Division at Stanford University Hospital. <h3>Technique</h3> Continuous ECG monitoring in an ambulatory patient requires a small portable tape
An Open Letter to Institutional Review Boards Considering Northfield Laboratories' PolyHeme<sup>®</sup>Trial
Authors: Ken Kipnis, Nancy M. P. King, Robert M. Nelson
Journal: The American Journal of Bioethics (2006)

At the time of this writing, a widely publicized, waived-consent trial is underway. Sponsored by Northfield Laboratories, Inc. (Evanston, IL) the trial is intended to evaluate the emergency use of PolyHeme, an oxygen-carrying resuscitative fluid that might prevent deaths from uncontrolled bleeding. The protocol allows patients in hemorrhagic shock to be randomized between PolyHeme and saline in the field and, still without consent, randomized between PolyHeme and blood after arrival at an emergency department. The Federal regulations that govern the waiver of consent restrict its applicability to circumstances where proven, satisfactory treatments are unavailable. Blood-the standard treatment for hemorrhagic shock-is not available in ambulances but is available in hospitals. The authors argue that the in-hospital stage of the study fails to meet ethical and regulatory standards.
Union Médicale du Canada, Montreal
Journal: JAMA (1964)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
AVERTIN NARCOSIS
Authors: G. Edwards
Journal: BMJ (1929)

AVERTIN has been used in this country for the last year anid a lhalf anid has been on the market for the last six moniths.During the last year I lave beeni pr-ivileged to w-ork with Dr. J. Blomfield and Dr. Z. Meninell, and was able to gain some knowledge of its uise.Avertin is tribromethylalcohol, a whito crystalline solid.It is soluble in water to the extent of 3i per cent.at body temperature.Wbhen heated above 400 Centigrade oexposed to light for long it decomposes into dibrom- acetaldeldvde and hydrobromic acid.The former substance is extremely irritating to the bowel; the hlidrobromic acid is readily observed by its reactioln with Conigo red reagent and pr-ovides a ready anid necessary means for testing the purity of avertin solutionis.
Retrospect of the Medical Sciences
Journal: BMJ (1842)

In a pamphlet published by Dr. Clement Ollivier, of Angers, on the treatment of prolapsus uteri, he speaks strongly against the use of differently shaped pessaries, which are employed indiscriminately, with- out paying attention to the cause of the prolapsus, which, according to Dr. Ollivier, is nothing more than an engorgement.Thence arise the symptoms which are constantly observed, and which are attributed to any cause other than the presence of a foreign body, and its contact with a painful and inflamed surface.M. Ollivier considers that one of the most frequent causes of this affection in young girls, with whom it is very rare, is masturbation.He says, that one of the most frequent causes of chronic engorgement of the uterus in virgins, or women who do not have any communication with men, is masturbation, which, by
Abstract 19157: Shocks During Cardioversions are Not Uncommonly Delivered Asynchronous Including in the Vulnerable Phase of the T-wave: A Post-hoc Analysis of a Randomized Controlled Study
Authors: Anders S Schmidt, Kasper G Lauridsen, Hans Rickers, Leif F Bach, Bo Løfgren
Journal: Circulation (2015)

Background: Shock synchronized to the QRS-complex is essential to avoid cardioversion induced ventricular fibrillation. Several defibrillators are used in clinical practice, but little is known about their ability to synchronize shocks in real life use. In a randomized study, comparing two defibrillators, a major adverse event occurred and was related to synchronization failure of one device. Aim: To investigate if shocks are delivered asynchronous during synchronized cardioversion. Methods: A post-hoc analysis of a randomized study enrolling patients admitted for elective cardioversion was performed. Patients were randomized to receive cardioversion by LIFEPAK 20 (Physio-Control Inc., Redmond, WA, USA) or Schiller Defigard 5000 (Schiller AG, Baar, Switzerland). All shocks were delivered with the defibrillators in synchronization modus. Post-hoc, we investigated the ability to synchronize, i.e. the delay between the R-wave and shock delivery, by reviewing electrocardiographic shock recordings. According to the Association for the Advancement of Medical Instrumentation and the American National Standards Institute, a synchronized shock should be delivered within 60 milliseconds after the R-wave. Results: A total of 134 patients were randomized; 65 patients received cardioversion by LIFEPAK 20 (mean age: 67 years, 14% atrial flutter), and 70 patients Schiller Defigard 5000 (mean age: 66 years, 14% atrial flutter). Overall, 138 shocks were delivered by LIFEPAK 20, all of them delayed more than 60 milliseconds (range: 80-200 milliseconds). All LIFEPAK 20 shocks were however delivered between the R-wave and the T-wave upstroke. In total, 193 shocks were delivered by Schiller Defigard 5000. Of these, 169 (88%) shocks were delivered within 60 milliseconds (range: 0-450 milliseconds), 180 (93%) between the R-wave and the T-wave upstroke, and 13 (7%) in the vulnerable part of the T-wave. Two of these shocks resulted in malignant ventricular tachycardia. Conclusion: Synchronized shocks in cardioversions are not uncommonly delivered asynchronous, including in the vulnerable phase of the T-wave. Of these shocks, two resulted in cardioversion induced malignant ventricular tachycardia.
Corrigendum: Crookes's Dark-adaptation Tester
Journal: BMJ (1940)

phenomenon lasted onliy for-some weeks or months, but in the case in question the haematospermia lasted on and off for twenty or-thirty years-in fact, till seminal emissions practically ceased after the age of 70 years or thereabout.The exact cause of this ordinary benign type of haematospernmia is not likely to be proved, as it does not appear to disturb the general health or shor-ten life, whatever the exact cause may be.At a post- mortem examination in old age the previous occurrence of fr-equent haem.atospermia is likely not to reach the ears of the
Highlights
Journal: JAMA (2017)

Trastuzumab Biosimilar in ERBB2-Positive Breast Cancer 37Biological agents, including monoclonal antibodies, improve outcomes for a number of cancers; however, access to these treatments is limited in many countries.Development of biosimilars-products highly similar to but not structurally duplicative of a reference product-could improve global availability of these drugs.In a randomized clinical trial involving 458 patients with ERBB2-positive metastatic breast cancer, Rugo and colleagues found that compared with trastuzumab-an anti-ERBB2 monoclonal antibody-treatment with a proposed trastuzumab biosimilar resulted in an equivalent overall response rate at 24 weeks.Two Editorials discuss biosimilars in cancer treatment and fi nancial obligations to ensure patient access to these therapies.Editorial 30 and 33 CME jamanetworkcme.com Zoledronic Acid Dosing Interval in Metastatic Bone Disease 48The optimal dosing interval for zoledronic acid, a bisphosphonate drug that reduces the incidence of skeletal-related events in patients with bone metastases, is uncertain.In a randomized, open-label clinical trial involving 1822 patients with bone metastases due to breast cancer, prostate cancer, or multiple myeloma, Himelstein and colleagues found that use of zoledronic acid every 12 weeks, compared with the standard dosing interval of every 4 weeks, did not result in an increased risk of skeletal events over 2 years.
Books Received.
Journal: JAMA (1900)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Prognostic Disclosure
Authors: Elizabeth B. Lamont
Journal: Annals of Internal Medicine (2002)

Letters3 September 2002Prognostic DisclosureElizabeth B. Lamont, MD, MS and Nicholas A. Christakis, MD, PhD, MPHElizabeth B. Lamont, MD, MSUniversity of Chicago; Chicago, IL 60637Harvard Medical School; Boston, MA 02115Search for more papers by this author and Nicholas A. Christakis, MD, PhD, MPHUniversity of Chicago; Chicago, IL 60637Harvard Medical School; Boston, MA 02115Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-137-5_Part_1-200209030-00021 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail IN RESPONSE:Drs. Webster, Grossman, and GuntherMaher each help to explain the results of our study by placing them within the social context of U.S. medicine. They suggest that constraints related to the societal concepts of “the physician,” “the patient,” and “the health care system” itself may lead physicians away from frank disclosure of prognoses to patients with cancer at the end of life. Regarding the physician, Dr. Webster suggests that until physicians stop viewing death as preventable and thus a professional failure, their efforts to cultivate good deaths for their patients will be scant (1). Regarding the patient, Dr. ...References1. Steinhauser KE, Clipp EC, McNeilly M, Christakis NA, McIntyre LM, Tulsky JA. In search of a good death: observations of patients, families, and providers. Ann Intern Med. 2000;132:825-32. [PMID: 10819707] LinkGoogle Scholar2. The AM. Hak T, Koëter G. van Der Wal G, Collusion in doctor-patient communication about imminent death: an ethnographic study. BMJ. 2000;321:1376-81. [PMID: 11099281] CrossrefMedlineGoogle Scholar Author, Article, and Disclosure InformationAffiliations: University of Chicago; Chicago, IL 60637Harvard Medical School; Boston, MA 02115 PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoIn Search of a Good Death: Observations of Patients, Families, and Providers Karen E. Steinhauser , Elizabeth C. Clipp , Maya McNeilly , Nicholas A. Christakis , Lauren M. McIntyre , and James A. Tulsky Prognostic Disclosure to Patients with Cancer near the End of Life Elizabeth B. Lamont and Nicholas A. Christakis Prognostic Disclosure James R. Webster Jr. Prognostic Disclosure David Grossman Prognostic Disclosure Michael GuntherMaher Prognostic Disclosure Michael GuntherMaher Prognostic Disclosure David Grossman Prognostic Disclosure James R. Webster Jr. Metrics 3 September 2002Volume 137, Issue 5_Part_1Page: 368-369KeywordsBehaviorDisclosureEmotionsEnd of life careHealth care ePublished: 3 September 2002 Issue Published: 3 September 2002 CopyrightCopyright © 2002 by American College of Physicians. All Rights Reserved.PDF DownloadLoading ...
THU0234 Familial mediterranean fever: analysis of 45 tunisian patients
Authors: SS Turki, CH Ben Taarit, R Goucha, E Abderrahim, F Ben Moussa, H Ben Maiz
Journal: Annals of the Rheumatic Diseases (2001)

<h3>Background</h3> Familial mediterranean fever (FMF) is an inherited multisystem disease of unknown aetiology, characterised by recurrent, painful, self-limited episodises. <h3>Objectives</h3> The objectives of this study is to describe the clinical profile, course and complications of 45 cases of FMF observed over a period of 25 years. <h3>Methods</h3> Retrospective review of 45 cases with FMF. <h3>Results</h3> Forty patients (88%) started their illness below the age of 10 years. Peritonitis occured in 84,4%, arthritis in 35,5%, pleuretis in 17,7% and erysipelas-like lesions in 31,1%. 21 patients developed renal amyloïdosis and 17 patients were subjected to unnecessary operative surgery. The arthritis was monoarticular in 85% and polyarticular in 15% and was seronegative in all cases (Rheumatoïd factor and antinuclear antibodies). The synovial attack showed a wide variation in the clinical presentation, course and duration of arthritis causing diagnostic difficulties. Renal amyloïdosis occured in 21 patients after a mean duration of FMF 10,5 years (2 to 28 years). One patient had hematuria, kidney biopsy showed mesangial IgA glomerulonephritis. Among 32 patients treated with colchicine, 80% achieved a therapeutic response. <h3>Conclusion</h3> FMF is an inherited disease; colchicine remains the only efficient treatment to prevent both acute manifestations and amyloïdosis.
Profiles of local African organisations doing research
Journal: BMJ (2005)

text, adequate technical capacity.Innovative approaches to developing capacity, such as health systems research including policy makers and practitioners, continuing education, and ongoing support all require commitment from local research and academic institutions.Rehabilitation of Africa's universities and research institutions to enable them to give this commitment will require considerable funding. 18ther urgent measures are necessary to revive Africa's failing health systems.A key imperative is to rapidly increase numbers of health workers and improve their functioning.Funds alone will be insufficient.Retention policies, including financial and non-financial incentives such as accelerated training, support, and supervision, are crucial. 18Effective mechanisms to limit or compensate for emigration of health workers are also needed.Current initiatives such as voluntary codes on recruitment have not worked, and attracting back Africans who have specialised overseas may strengthen the lobby for high-tech approaches to health care.